

Mark C Markowski

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8512453/mark-c-markowski-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

404
citations

12
h-index

19
g-index

39
ext. papers

663
ext. citations

4.9
avg, IF

4
L-index

#	Paper	IF	Citations
32	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with F-DCFPyL. <i>Molecular Imaging</i> , 2022 , 2022, 7056983	3.7	0
31	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. <i>European Urology Open Science</i> , 2022 , 41, 112-115	0.9	0
30	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 5948-5962	10.1	3
29	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1371-1382	2.2	22
28	The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	1
27	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021 , 79, 692-699	10.2	17
26	Detection of Early Progression with F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1270-1273	8.9	1
25	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021 , 80, 632-640	10.2	14
24	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 1430-1437	8.9	4
23	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , 2021 , 144, 302-309	7.5	3
22	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	3
21	Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes. <i>Urology</i> , 2021 , 154, 201-207	1.6	1
20	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. <i>Journal of Urology</i> , 2021 , 206, 623-629	2.5	0
19	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , 2020 , 20, 492	4.8	6
18	Advanced renal cell carcinoma and COVID-19 - a personal perspective. <i>Nature Reviews Urology</i> , 2020 , 17, 425-427	5.5	6
17	Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. <i>Prostate</i> , 2020 , 80, 407-414	4.2	11
16	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2020 , 204, 496-502	2.5	9

15	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz093	4.6	62
14	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 948-956	4	21
13	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 470-475.e31	3.3	9
12	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019 , 19, 572	4.8	2
11	Cutaneous finger and tongue metastases in renal cell carcinoma. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	2
10	Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [F]DCFPyL PET/CT. <i>Molecular Imaging and Biology</i> , 2019 , 21, 567-573	3.8	28
9	The Microbiome and Genitourinary Cancer: A Collaborative Review. <i>European Urology</i> , 2019 , 75, 637-646	10.2	55
8	Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. <i>Prostate</i> , 2018 , 78, 992-1000	4.2	1
7	Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e839-e842	3.3	4
6	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1391-1397	5.9	19
5	Cancer Genetics, Cancer Biology, and Tumor Growth and Metastasis 2017 , 1-18		
4	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	32
3	Early use of chemotherapy in metastatic prostate cancer. <i>Cancer Treatment Reviews</i> , 2017 , 55, 218-224	14.4	12
2	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. <i>Prostate</i> , 2016 , 76, 1484-1490	4.2	25
1	Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e417-22	3.3	